Cellect Biotechnology Ltd (Nasdaq: APOP), a developer of a novel stem cell manufacturing technology, is opening a US centre of operations to be led by Andrew Sabatier, it was reported yesterday.

Sabatier has more than 20 years of experience in the Biotechnology/Life Sciences market, most recently with GE Cell Therapy, as the Sales and Market Development leader for the US and Canada. Prior to GE, from 2010 to 2017, he was the VP of Sales for BIOSAFE America, which was acquired by GE. He was responsible for creating the foundation committed to developing the cell processing market, which became the largest market for BIOSAFE, and is currently the cornerstone of GE's cell therapy business. He has managed US commercial operations and built, trained and developed international sales teams across Asia, South America, Europe, Canada, and the United States. Prior to joining BIOSAFE, Sabatier served in sales roles with Independent Health Care Consulting, Gambro, Genzyme, Cook Medical and Toshiba.

Sabatier said, 'Cellect is a leader in Regenerative Medicine enabling technology. We see an upcoming surge in demand for stem cells as raw material for a wide range of soon to be FDA approved novel therapies. It is a multi-billion-dollar potential business and a new industry in the making. I am happy to be a part of this journey to bring 21st century remedies to millions of patients worldwide.'